Skip to main content

Two-Step RP Purification of Tirzepatide

Scaling Up Tirzepatide Purification: From 20% Crude to >99% Purity
With the surge in demand for GLP-1 receptor agonists, efficient and scalable purification strategies for complex lipopeptides like Tirzepatide have never been more critical.

In this latest Application Note by YMC, learn how a two-step Reverse Phase (RP) purification strategy achieves exceptional results:
► Step 1 (Bulk Impurity Removal): YMC-Triart Prep Bio200 C8 boosts initial purity from 20% crude up to 93%.
► Step 2 (Polishing): YMC-Triart Prep C4-S operating at pH 8.0 delivers a final HPLC purity of 99.7%.

The hybrid-silica base of the YMC-Triart Prep series allows for operation at higher pH levels, overcoming a major limitation of traditional silica-based phases and enabling optimal resolution for challenging peptides.

Download the Application Note.

Posted on July 30, 2026.

Related Posts

September 4, 2026

YMC America Brings U.S.-Supplied ASME U-Stamped DAC Columns to Pharmaceutical Manufacturers

YMC America will be the First U.S.-Based Supplier of ASME U-Stamped DAC Columns. The company’s DAC columns support pharmaceutical and biopharmaceutical customers from process development through commercial production. Systems are used in laboratory, pilot, and production-scale chromatography applications, including purification processes for peptides, oligonucleotides, and small-molecule APIs.

September 9, 2026

Tecnologias Analíticas para Peptídeos Terapêuticos- Portuguese

Os peptídeos terapêuticos são uma classe emergente de insumos farmacêuticos ativos que, juntamente com outras classes de bioprodutos, vêm despertando grande interesse devido às suas vantagens únicas.

September 9, 2026

Tecnologías Analíticas para Péptidos Terapéuticos- Spanish

El primer péptido estudiado en este campo fue la insulina, una cadena de 51 aminoácidos que fue aislada originalmente en 1921 por Frederick Banting y Charles Best y que posteriormente se convirtió en el primer péptido disponible comercialmente (1923). Actualmente, existe una extensa lista de péptidos disponibles comercialmente en el mercado, incluidos los conocidos análogos de GLP-1, como liraglutida, semaglutida y tirzepatida.

Designed and developed by